Cocaine-induced chromatin remodeling increases brain-derived neurotrophic factor transcription in the rat medial prefrontal cortex, which alters the reinforcing efficacy of cocaine.
Cocaine self-administration alters patterns of gene expression in the brain that may underlie cocaine-induced neuronal plasticity. In the present study, male Sprague Dawley rats were allowed to self-administer cocaine (0.25 mg/infusion) 2 h/d for 14 d, followed by 7 d of forced abstinence. Compared with yoked saline control rats, cocaine self-administration resulted in increased brain-derived neurotrophic factor (BDNF) protein levels in the rat medial prefrontal cortex (mPFC). To examine the functional relevance of this finding, cocaine self-administration maintained under a progressive ratio schedule of reinforcement was assessed after short hairpin RNA-induced suppression of BDNF expression in the mPFC. Decreased BDNF expression in the mPFC increased the cocaine self-administration breakpoint. Next, the effect of cocaine self-administration on specific BDNF exons was assessed; results revealed selectively increased BDNF exon IV-containing transcripts in the mPFC. Moreover, there were significant cocaine-induced increases in acetylated histone H3 (AcH3) and phospho-cAMP response element binding protein (pCREB) association with BDNF promoter IV. In contrast, there was decreased methyl-CpG-binding protein 2 (MeCP2) association with BDNF promoter IV in the mPFC of rats that previously self-administered cocaine. Together, these results indicate that cocaine-induced increases in BDNF promoter IV transcript in the mPFC are driven by increased binding of AcH3 and pCREB as well as decreased MeCP2 binding at this BDNF promoter. Collectively, these results indicate that cocaine self-administration remodels chromatin in the mPFC, resulting in increased expression of BDNF, which appears to represent a compensatory neuroadaptation that reduces the reinforcing efficacy of cocaine.
Sadri-Vakili
Ghazaleh
G
MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02129-4404, USA. gsadrivakili@partners.org
Kumaresan
Vidhya
V
Schmidt
Heath D
HD
Famous
Katie R
KR
Chawla
Prianka
P
Vassoler
Fair M
FM
Overland
Ryan P
RP
Xia
Eva
E
Bass
Caroline E
CE
Terwilliger
Ernest F
EF
Pierce
R Christopher
RC
Cha
Jang-Ho J
JH
D000818:Animals; D016739:Behavior, Addictive / Q000378:metabolism / Q000523:psychology; D019208:Brain-Derived Neurotrophic Factor / Q000096:biosynthesis* / Q000235:genetics*; D042002:Chromatin Assembly and Disassembly / Q000187:drug effects* / Q000502:physiology*; D003042:Cocaine / Q000008:administration & dosage* / Q000494:pharmacology; D019970:Cocaine-Related Disorders / Q000378:metabolism / Q000523:psychology; D008297:Male; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012054:Reinforcement, Psychology; D012646:Self Administration; D014158:Transcription, Genetic / Q000187:drug effects / Q000502:physiology; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology
D019208:Brain-Derived Neurotrophic Factor; D003042:Cocaine
Pharmacol Rev. 2002 Mar;54(1):1-42
11870259
Eur J Neurosci. 2002 Jun;15(12):2016-26
12099907
Mol Psychiatry. 1996 Jul;1(3):190-9
9118343
J Neurosci. 2002 May 1;22(9):3663-72
11978842
Neuropsychopharmacology. 2003 Aug;28(8):1485-90
12784114
Neuroscience. 2001;108(3):371-80
11738252
Science. 2003 Oct 31;302(5646):885-9
14593183
Psychol Rev. 1974 Mar;81(2):119-45
4817611
J Neurosci. 1994 Mar;14(3 Pt 1):1262-70
8074747
Trends Neurosci. 2005 Aug;28(8):436-45
15982754
J Neurosci. 2005 Dec 7;25(49):11444-54
16339038
Nat Neurosci. 2005 Nov;8(11):1440-1
16251984
Nat Neurosci. 2005 Nov;8(11):1437-9
16251983
J Neurosci. 2009 Mar 25;29(12):3715-9
19321768
J Neurosci. 2008 Jan 30;28(5):1118-30
18234890
J Virol. 1998 Mar;72(3):2224-32
9499080
Am J Psychiatry. 2005 Aug;162(8):1473-82
16055768
Eur J Neurosci. 2007 Nov;26(10):2756-63
18001273
J Neurosci. 2006 Sep 20;26(38):9656-65
16988036
J Neurosci. 2008 Sep 17;28(38):9342-8
18799668
Mol Ther. 2006 Jan;13(1):67-76
16260185
Eur J Neurosci. 1996 Aug;8(8):1696-706
8921260
Neuroreport. 2005 Feb 8;16(2):175-8
15671872
Addict Biol. 2005 Mar;10(1):101-18
15849024
Brain Res. 2010 Feb 16;1314:183-93
19732758
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11024-31
11572963
J Pharmacol Exp Ther. 2003 Nov;307(2):450-9
12966149
Nat Neurosci. 2007 Aug;10(8):1029-37
17618281
Brain Res. 1997 Feb 21;749(1):120-6
9070635
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11854-9
12192090
Nat Rev Neurosci. 2004 Jun;5(6):483-94
15152198
Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19186-91
16380431
Neuron. 2005 Oct 20;48(2):303-14
16242410
J Neurosci. 2004 Feb 18;24(7):1604-11
14973246
Neurosci Biobehav Rev. 2006;30(2):215-38
16099045
Hum Mol Genet. 2007 Jun 1;16(11):1293-306
17409194
J Neurosci. 1999 May 15;19(10):4110-22
10234039
J Neurosci Methods. 1980 Dec;3(2):129-49
6110810
Nat Neurosci. 2005 Nov;8(11):1445-9
16251986
Mol Pharmacol. 2006 Aug;70(2):487-92
16670375
Science. 2003 Oct 31;302(5646):890-3
14593184
Hum Gene Ther. 1999 Apr 10;10(6):1031-9
10223736
J Neurosci Res. 2007 Feb 15;85(3):525-35
17149751
Methods Mol Biol. 2004;277:261-76
15201461
J Neurosci. 1999 Oct 1;19(19):8685-95
10493769
Neurobiol Dis. 2006 May;22(2):233-41
16442295
Brain Res. 2006 Jan 5;1067(1):1-12
16376315
Eur J Neurosci. 2007 Aug;26(3):757-66
17651427
J Neurochem. 2003 May;85(4):911-24
12716423
Neuron. 2007 Nov 8;56(3):517-29
17988634
J Neurosci Methods. 1996 May;66(1):1-11
8794935
Brain Res Mol Brain Res. 1994 Feb;21(3-4):206-18
8170345
Neuropharmacology. 2004;47 Suppl 1:24-32
15464123
J Neurosci. 2003 Feb 1;23(3):742-7
12574402
J Psychopharmacol. 1999 Dec;13(4):337-45
10667609
Neuropsychopharmacology. 2008 Jul;33(8):1807-17
17851536
J Neurochem. 2002 Sep;82(6):1453-64
12354293
Biol Psychiatry. 2007 Jul 1;62(1):55-64
16945350
Neuron. 1993 Mar;10(3):475-89
8461137